Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could BCG and MMR vaccines tame COPD inflammation?

NCT ID NCT06257212

Disease control Sponsor: Josefin Eklöf Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether giving live vaccines (BCG and MMR) to people with COPD can train their immune system to produce less harmful inflammation. Sixty adults with COPD received either the vaccines or a placebo. Researchers measured changes in immune cell activity over four months to see if the vaccines could reduce systemic inflammation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BCG vaccine (Danish strain 1331) and MMR vaccine
What this could lead to
If it works, this could point toward a new way to reduce harmful inflammation in COPD using existing vaccines.
What could go wrong
This is a small pilot study with only 60 participants, so results may not apply widely. The vaccines also carry risks like allergic reactions or fever.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

60 people

The number who actually took part.

Started

Feb 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Specialist verified and spirometry-confirmed COPD * Age \> 40 years. * Negative HIV-test. * Able to give informed consent. Exclusion Criteria: * Acute febrile illness. * Known allergy to BCG or MMR vaccines or serious adverse effects at previous vaccination. * Allergy to MMR vaccine components, neomycin, or egg proteins. * Known prior, active, or latent infection with mycobacterium tuberculosis. * Pregnancy or breastfeeding. * Vaccination with a live vaccine within the last 4 weeks. * Being severely immunocompromised (HIV-1 infection, organ- or bone marrow transplantation, chemotherapy, primary immune defect, anti-cytokine therapy, immunosuppressant treatment). * Oral or intravenous corticosteroid at dose of ≥10 mg/day with duration over 3 months. * Active solid or non-solid malignancy or lymphoma, excluding basal cell carcinoma within 2 years. * Treatment with immunoglobulins within the last 3 months or expected treatment with immunoglobulins for the duration of the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD Trained innate immunity

Contacts and locations

Locations

  • Department of Internal Medicine, Section of Respiratory Medicine

    Hellerup, Copenhagen, 2900, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.